Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies-Reference-Cited by-同舟云学术

Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies

Published:2013-01-17 Issue:1 Volume:9 Page:e1003220
ISSN:1553-7404
Container-title:PLoS Genetics
language:en
Short-container-title:PLoS Genet

Author:

Vijai Joseph,Kirchhoff Tomas,Schrader Kasmintan A.,Brown Jennifer,Dutra-Clarke Ana Virginia,Manschreck Christopher,Hansen Nichole,Rau-Murthy Rohini,Sarrel Kara,Przybylo Jennifer,Shah Sohela,Cheguri Srujana,Stadler Zsofia,Zhang Liying,Paltiel Ora,Ben-Yehuda Dina,Viale Agnes,Portlock Carol,Straus David,Lipkin Steven M.,Lacher Mortimer,Robson Mark,Klein Robert J.,Zelenetz Andrew,Offit Kenneth

Publisher

Public Library of Science (PLoS)

Subject

Cancer Research,Genetics (clinical),Genetics,Molecular Biology,Ecology, Evolution, Behavior and Systematics

Reference40 articles.

1. From the REAL classification to the upcoming WHO scheme: A step toward universal categorization of lymphoma entities?;SA Pileri;Ann Oncol,1998

2. The risk of lymphoma development in autoimmune diseases: a meta-analysis;E Zintzaras;Arch Intern Med,2005

3. The genetics of familial lymphomas;R Siddiqui;Curr Oncol Rep,2004

4. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32;L Conde;Nat Genet,2010

5. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma;CF Skibola;Nat Genet,2009

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Male Breast Cancer: Current Scenario and Future Perspectives;Technology in Cancer Research & Treatment;2024-01

2. Elucidating the Correlation between Leupaxin as a Prognostic Biomarker and Immunotherapeutic Efficacy in Esophageal Squamous Cell Carcinoma;2023-12-20

3. Leupaxin: A Prospective Therapeutic Target for Esophageal Squamous Carcinoma Treatment;2023-11-10

4. Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia;Journal of Clinical Oncology;2023-02-10

5. Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer;Cancers;2022-11-17